Trombosis pada corona virus disease (COVID-19)
Abstract
Abstrak. Coronavirus Disease 2019 (COVID-19) telah menyebabkan masalah kesehatan di seluruh dunia dengan morbiditas dan mortalitas yang terus meningkat. Pada beberapa kasus COVID-19 diketahui terjadi manifestasi trombotik. Adanya kelainan trombotik ini tentunya mempengaruhi tatalaksana dan prognosis pasien COVID-19. Oleh karena itu penting untuk mengetahui patofisiologi dan manajemen trombosis pada COVID-19. Tujuan dari artikel ini adalah mengulas literatur terbaru terkait prevalensi, patofisiologi, penilaian risiko, serta manajemen trombosis pada COVID-19.
Kata kunci: COVID-19, trombosis.
Abstract. Coronavirus Disease 2019 (COVID-19) has become a global health problem with ever increasing morbidity and mortality. In some cases, thrombotic manifestation has been reported in COVID-19 patients. This thrombotic manifestation certainly affects the management and prognosis of COVID-19 patients. Therefore it is crucial to understand the pathophysiology and management of thrombosis in COVID-19. The aim of this article is to review the recent literature regarding prevalence, pathophysiology, risk assessment, and management of thrombosis in COVID-19.
Keywords:COVID-19, thrombosis
Keywords
References
Daftar pustaka
Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727–733.
WHO. WHO Coronavirus Disease (COVID-19) Dashboard, https://covid19.who.int/ (2020, diakses 20 Juli 2020).
Roache M. Europe’s Second Wave of COVID-19 is Being Driven by Two Countries. Here’s Why. TIME,https://time.com/5902172/europe-coronavirus-second-wave-belgium-czech-republic/ (diakses 30 Oktober 2020).
BNPB. Situasi COVID-19 Indonesia, https://bnpb-inacovid19.hub.arcgis.com/app/indonesia-covid-19-dashboard (diakses 20 Oktober 2020).
Aditya A. Indonesia Overtakes Philippines With Most Covid Cases in Southeast Asia. Bloomberg, https://www.bloomberg.com/news/articles/2020-10-15/indonesia-becomes-site-of-southeast-asia-s-worst-virus-outbreak (diakses 18 Oktober 2020).
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507–513.
Liu B, Li M, Zhou Z, et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 2020; 111:102452.
Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020; 191: 148–150.
Bompard F, Monnier H, Saab I, et al. Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J 2020; 56: 2001365.
Middeldorp S, Coppens M, Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemost 2020; 18: 1995–2002.
Zhang C, Shen L, Le K-J, et al. Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis. Front Cardiovasc Med; 7. Epub ahead of print 6 Agustus 2020. DOI: 10.3389/fcvm.2020.00151.
Poissy J, Goutay J, Caplan M, et al. Pulmonary Embolism in Patients With COVID-19. Circulation 2020; 142: 184–186.
Huertas A, Montani D, Savale L, et al. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Eur Respir J 2020; 56: 2001634.
Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med 2020; 46: 1603–1606.
Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020; 10: 102–108.
Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–1418.
Price LC, McCabe C, Garfield B, et al. Thrombosis and COVID-19 pneumonia: the clot thickens! Eur Respir J 2020; 56: 2001608.
Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46: 1089–1098.
Colling ME, Kanthi Y. COVID–19-associated coagulopathy: An exploration of mechanisms. Vasc Med 2020; 25: 471–478.
Castelli R, Gidaro A. Abnormal Hemostatic Parameters and Risk of Thromboembolism Among Patients With COVID-19 Infection. J Hematol 2020; 9:1–4.
Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost 2020; 18: 1023–1026.
Bikdeli B, Madhavan M V., Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. J Am Coll Cardiol 2020; 75:2950–2973.
Pangarsa EA, Setiawan B, Santosa D, et al. Position paper from the Indonesian Society of Thrombosis and Hemostasis (InaSTH), Semarang chapter: Management of coagulopathy in COVID-19. Bali Med J 2020;9 482–488.
Iba T, Nisio M Di, Levy JH, et al. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open 2017; 7: e017046.
Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost 2019; 17: 1989–1994.
Spyropoulos AC, Anderson FA, FitzGerald G, et al. Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE. Chest 2011; 140: 706–714.
Abou-Ismail MY, Diamond A, Kapoor S, et al. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res 2020; 194: 101–115.
Ikatan Dokter Indonesia. Rekomendasi IDI pemberian antikoagulan profilaksis pada pasien COVID-19 yang dirawat di rumah sakit, https://www.pdspatklin.or.id/assets/files/pdspatklin_2020_09_30_22_58_39.pdf (diakses 19 Oktober 2020).
Hunt B, Retter A, McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19, https://b-s-h.org.uk/media/18171/th-and-covid-25-march-2020-final.pdf (diakses 20 Oktober 2020).
Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood 2020; 136: 1347–1350.
Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2020; 50: 72–81.
Cuker A, Tseng EK, Nieuwlaat R, et al. ASH 2020 guidelines on the use of anticoagulation in patients with COVID-19: Draft recommendations. American Society of Hematology, https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19 (diakses 20 Oktober 2020).
Lee A, DeSancho M, Pai M, et al. COVID-19 and Pulmonary Embolism: Frequently Asked Questions. American Society of Hematology, https://www.hematology.org/covid-19/covid-19-and-pulmonary-embolism (diakses 20 Oktober 2020).
Oudkerk M, Büller HR, Kuijpers D, et al. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. Radiology 2020;297:E216–E222
DOI: 10.24815/jks.v20i3.18689
Refbacks
- There are currently no refbacks.